ChronicleBio key facts
- Developer of a decentralized research ecosystem designed to advance the understanding and treatment of complex neuroimmune disorders.
- It has raised $5.4M; the latest was Seed Round ($5.4M) in Jan 2026.
- Notable investors include Electric Capital, Tarsadia Investments, Wisdom Ventures Fund.
- Status: Privately Held (backing).
ChronicleBio leadership
- John MummChief Scientific Officer
Who backs ChronicleBio
3- ·Watch ChronicleBio: the Monday email on marks, rounds and moves
ChronicleBio funding rounds
No funding rounds for ChronicleBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ChronicleBio investors
3 investors are on record for ChronicleBio, including Electric Capital, Tarsadia Investments and Wisdom Ventures Fund.
Who runs ChronicleBio
6 people are listed on the ChronicleBio team: 1 executive and 5 board members, including John Mumm (Chief Scientific Officer). 6 of them have a verified direct contact on file.
About ChronicleBio
Developer of a decentralized research ecosystem designed to advance the understanding and treatment of complex neuroimmune disorders. The company's data-driven healthcare platform offers a comprehensive platform that integrates multi-omic data, real-time symptom tracking, and a secure biobank, enabling researchers and clinicians to create personalized diagnostics and therapeutic strategies to help diagnose and treat patients with chronic illnesses.
- Sector
- Healthcare
- HQ
- West Valley City, UT, United States
- Founded
- 2025
- Employees
- 9
- Website
- chroniclebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
ChronicleBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.